Text Size

Systemic expression of Alu RNA in patients with geographic atrophy secondary to age-related macular degeneration

Yoshida H., Matsushita T., Kimura E., Fujita Y., Keany R., Ikeda T., Toshimori M., Imanaka T., Nakamura M.


  • 2019
  • PLoS ONE
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Other

  • Affiliations

    Research and Development Division, Santen Pharmaceutical Co., Ltd., Osaka, Japan; Research and Development Division, Santen Inc., Emeryville, CA, United States

Related Publications

The growing burden of myopia in Europe: evidence from population-based cohorts

Tiemens A., van Hemert D.J., Lemma S.T., Quist S.W., Shi-van Wielink K., Agius D., Arnould L., Berendschot T.T.J.M., Beuse A., Bikbov M.M., Birtel J., Bountziouka V., Breteler M.M.B., Carbonaro F., Chakravarthy U., Coimbra R., de Vries V.A., Delcourt C., Farinha C., Finger R.P., Ghanbari M., Giannoulis D.A., Grohmann C., Hammond C.J., European Eye Epidemiology (E3) Consortium


Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes

Jovanović J., Zacharioudaki M., Kalatzi M., Papadakis G., Mulkalapalli N., Ernst F., de Milliano T.


Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022